Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

F. J. Giles, P. D. Le Coutre, J. Pinilla-Ibarz, R. A. Larson, N. Gattermann, O. G. Ottmann, A. Hochhaus, J. P. Radich, G. Saglio, T. P. Hughes, G. Martinelli, D. W. Kim, S. Novick, K. Gillis, X. Fan, J. Cortes, M. Baccarani, H. M. Kantarjian

Research output: Contribution to journalArticlepeer-review

157 Scopus citations

Fingerprint

Dive into the research topics of 'Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study'. Together they form a unique fingerprint.

Medicine & Life Sciences